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Urinary neutral endopeptidase 24.11 activity: Modulation by chronic
salt loading. Neutral endopeptidase (NEP) 24.11 is a zinc-metallopepti-
dase involved in the metabolism of several biologically active peptides
including enkephalin, atrial natriuretic peptide, bradykinin, and endothe-
lin. The enzyme is found in abundant amounts in the brush border of renal
proximal epithelial cells. A soluble form of NEP was previously identified
in human urine with characteristics similar to the renal enzyme. The
present study further characterized the excreted form of NEP activity in
urine of normal rats using a sensitive two-stage enzymatic assay. The
response of urinary NEP to known inhibitors such as phosphoramidon and
thiorphan, and its dependence on pH and salt concentration was studied.
In addition, we evaluated the effects of acute and chronic changes in salt
balance, induced by i.v. saline infusion and drinking of saline solution, on
urinary NEP and on the activity of the enzyme in isolated proximal
tubules. Our findings demonstrated that abundant NEP activity was
detected in the urine of normal rats. Furthermore, chronic salt loading,
but not acute salt infusion, was associated with increased activity of NEP
in urine and in isolated proximal tubules, suggesting that the enzyme may
be regulated by salt balance. Finally, the data suggest that urinary NEP
may be used as an index of enzyme activity in the kidney.
Neutral endopeptidase (NEP) 24.11 is a zinc-metallopeptidase
originally identified in the brush border of proximal nephron from
rabbit kidney [1]. The enzyme cleaves peptides at the amino group
of hydrophobic residues and is involved in the degradation of
several peptides with important biological activities. These in-
clude the endogenous opioid-like neuropeptide enkephalin [2],
atrial natriuretic peptide (ANP) [3], bradykinin [4], and endothe-
lin [5].
NEP has been identified in a variety of nonrenal tissues
including the brain, intestine, lung and seminal vesicles [6]. Also,
the common acute lymphoblastic leukemia antigen (CALLA, or
CD1O) has been shown to be identical with human NEP [7]. The
enzyme is found in abundant amounts in the kidney, primarily in
the microvilli of the proximal nephron cells, but also in the
glomeruli of human, rabbit and dog [8—10]. It is currently assumed
that NEP plays a role in the in vivo degradation of several peptide
hormones for which the kidney serves as an important target
organ. Thus, selective inhibition of NEP activity by specific
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blockers is associated with increased urinary excretion of ANP
and its second messenger cyclic guanosine monophosphate, natri-
uresis, and prolongation of the half-life of ANP [ii, 12]. Similarly,
the excretion of endothelin in the urine and that of bradykinin are
also increased following NIEP inhibition [4, 13]. These peptides
participate in the regulation of renal hemodynamics and urinary
sodium excretion, either as circulating hormones or in a paracrine
mode of action. The involvement of this enzyme in the degrada-
tion of the natriuretic peptide family [14] has led to the hypothesis
that alterations in the endogenous renal NEP activity may exist in
situations associated with deranged sodium homeostasis such as
congestive heart failure [15, 16]. However, direct measurements
of renal NEP activity to support the latter possibility are not
available. Moreover, it is not known at present whether the
activity of the enzyme in the kidney is influenced by sodium
balance under normal physiological conditions.
An excreted form of NEP was previously identified in human
urine by Skidgel et al [17]. The urinary enzyme appears to be of a
molecular size similar to the renal enzyme. Furthermore, both the
purified renal NEP and the urinary enzyme were inhibited to the
same extent by phosphoramidon and thiorphan, and the activity of
the urinary enzyme was inhibited by specific antiserum against the
renal NEP [17]. These findings suggest that urinary enzyme is of
renal origin and, therefore, that urinary NEP might reflect the
activity of the enzyme in the kidney. The latter assumption is also
supported by the following reasoning: First, NEP is an ectoen-
zyme, that is, it is present on the surface of the epithelial tubular
cells and therefore may appear in the urine like other peptides of
tubular origin. Moreover, data are now available to indicate that
a major portion of the enzyme (93% of the total amino acid
sequence), including the active site, is present in the extracellular
domain [18, 19]. Second, because of its large size, 94 kilodaltons,
the enzyme is apparently not filtered by the glomerulus, suggest-
ing that urinary NEP is largely of renal origin. Finally, NEP is a
relatively stable protein which resists significant proteolytic action,
which might explain why the excreted enzyme remains active in
urine.
Thus, the present study was undertaken with two main objec-
tives: (1) to characterize the activity of NEP in the urine of normal
rats and to define standard assay conditions for its measurement,
and (2) to evaluate the effects of acute and chronic alterations in
sodium intake on renal and urinary NEP activity.
The data to be presented indicate that NEP is found in
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abundant amounts in the urine. Moreover, our findings further
indicate that the activity of the enzyme in the kidney and the urine
may be modulated by chronic alterations in sodium intake.
Methods
Studies were conducted on a local strain of male Wistar rats
(200 to 250 g) maintained on a standard rat chow (0.6% NaC1)
and tap water ad libitum. The animals were placed in individual
metabolic cages for daily monitoring of urine output and sodium
excretion. Urine was collected on a 24 hour basis, aliquots were
used for measurements of sodium concentration, and the rest was
frozen and stored at —70°C for determination of NEP activity.
Experimental protocols
To evaluate the effect of alterations in sodium intake on urinary
NEP activity, two experimental maneuvers were undertaken. A
group of 14 animals were placed in individual metabolic cages,
and urine was collected for five days (baseline period). On the
sixth day the drinking water was replaced by normal saline (0.9%
NaC1) for five additional days (days 6 to 10). On the eleventh day
five animals were anesthetized by i.p. injection of sodium pento-
barbital (40 mg/kg), their kidneys were removed through a
midline incision, and proximal tubules were isolated (see below).
In the remaining nine rats, saline was replaced by tap water for
another five days (recovery period, days 11 to 16). An additional
group (N = 5) was maintained on tap water throughout the
experiment and served as a time control. Four additional control
animals were sacrificed on the eleventh day, and suspensions of
isolated proximal tubules were prepared from their renal cortices.
Acute studies
Six Wistar rats (250 to 300 g) were anesthetized by i.p. injection
of 5-sec-butyl-5-ethyl-2 thiobarbituric acid (100 mg/kg, mactin,
Byk, Guldens, Germany) and prepared for clearance studies.
Following tracheostomy, the carotid artery and jugular vein were
cannulated by polyethylene tubing, PE50, for recording of mean
arterial pressure, blood sampling, and infusion of various solu-
tions. The urinary bladder was catheterized via a suprapubic
incision for urine collection. A solution containing 2% inulin in
normal saline was infused throughout the experiment at a rate of
1.5 ml/hr. The total volume of saline administered was adjusted by
another syringe pump to equal 1% of body weight. After a
one-hour equilibration period, a 30-minute baseline clearance
collection was obtained. The rate of saline infusion was then
increased to equal 5% of body weight administered in 20 minutes.
Four additional clearance periods of 20 minutes each were
obtained in the volume expansion state. Urine flow was matched
by an equivalent i.v. infusion of saline. Blood samples (0.3 ml)
were obtained at the midpoint of each clearance period. Blood
and urine samples were analyzed for inulin and sodium concen-
trations. Urine aliquots were frozen and kept at —70°C until
assayed for NEP activity.
Preparation of isolated proximal nephrons
Suspensions of isolated proximal tubules were prepared accord-
ing to the method of Vinay, Gougoux and Lemieux [20] with slight
modifications. Following anesthesia with sodium pentobarbital,
the kidneys were rapidly removed and placed in ice-cold Krebs-
Henseleit saline (KHS) of the following composition (in mM):
NaCl 140, KCI 3, NaH2PO4 1, MgC12 1, CaCI2 1, glucose 5 (pH
7.4). After decapsulation the cortices were dissected, placed in
KI-IS (10 mug tissues), and minced with a razor blade. The minced
tissue was transferred into 10 ml 1(1-IS containing 0.8 mg/mI Type
I collagenase (Clostridium histolyticum, Sigma, St. Louis, MO,
USA) and 5 mg/mI bovine serum albumin (Fraction V, Sigma)
and incubated for one hour at 37°C. The mixture was then
centrifuged for one minute at 300 rpm, and the supernates were
discarded twice. The tubules were then incubated in the cold with
bovine serum albumin (0.5 g/ml) for 10 minutes, pelleted, and
resuspended in 40 ml ice-cold 2X concentrated KHS:Percoll
mixture (1:1, 14 mOsm/kg; Pharmacia LKB, Uppsala, Sweden)
previously gassed with 95% 02 — 5% CO2 for 30 minutes. The
Percoll solution was centrifuged at 12,000 g for 30 minutes at 4°C.
The lowermost band, containing fragments of proximal tubules,
was collected and resuspended in Percoll solution diluted with
1(1-IS (1:2 to 1:3). The purity of the suspension, as evaluated by
microscopic inspection, was >95%. Tubules were pelleted by
microcentrifuge and stored at —20°C.
Determination of NEP 24.11 activity
The activity of NEP in urine samples and in isolated proximal
tubular suspensions was assayed with a sensitive two-stage enzy-
matic reaction [21] using the substrate 3-carboxypropranoyl-
alanyl-alanyl-Ieucine-4 nitroanilide supplemented with bacterial
(Streptomyces griseus) aminopeptidase I (SGAPI). The substrate is
initially attacked at the alanyl-leucine bond by NEP 24.11, making
the leucine-4-nitroanilide moiety available to SGAPI, with a
concomitant increase of absorption at 405 nm due to the release
of 4-nitroaniline (E405 = 10,600 M 1cm 1)• This assay is able to
detect femtomolar concentrations of NEP [21].
Urine samples (4 to 5 11) or aliquots of tubular suspensions
(containing 10 to 20 g protein) were micropipetted and placed in
a 96-well microtiter plate with 200 tl of Buffer A (100 mri NaCI,
10 mM CaCI2, 50 mrvi Tris titrated to pH 7.91 with HCI, 0.4 mM
substrate, and 6.5 igIml SGAPI) heated to 37°C. Reactions were
carried out in a thermoregulated automated microplate reader
(Ceres 900, Biotek Instruments, Winooski, VT, USA) for 25 to 30
minutes after a five-minute preincubation period. Under these
conditions, linear plots of the absorbance changes were recorded,
allowing for a maximal reaction rate of 10 mOD/mm. The activity
of NEP in urine was normalized to urinary creatinine concentra-
tion and expressed as mOD min1 j.g' creatinine. In the
clearance experiments the enzyme activity in urine was normal-
ized per milligram inulin. NEP activity in tubular suspensions was
expressed per ig of protein as determined by the Lowry method
[22] adapted to microsamples.
Enzyme activity may vary upon changes in temperature, pH,
and ionic strength of the medium. In the present study NEP
activity was determined at 37°C unless otherwise specified. More-
over, to account for the possible large variations in urinary pH and
ionic strength, standard assay conditions were chosen based upon
preliminary experiments in which the effects of changes in pH
(range, 5.6 to 9.2) and sodium concentrations (0.1 to 2.0 M) on
urinary NEP activity were studied. In an additional set of exper-
iments the inhibitory effects of known blockers of NEP 24.11,
phosphoramidon (Peninsula Laboratories, Belmont, CA, USA)
and thiorphan (Sigma) were studied on enzyme activity in the
urine.
Stock solutions containing 1 m concentrations of the inhibi-
tors in 10 mM Tris-HC1 buffer, pH 7.4, were prepared. Successive
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dilutions (1:10) were performed with Buffer A (without substrate
and SGAPI) to a final concentration range (10—i to 10' M) of
the inhibitor. Urine samples were added to the inhibitor-buffer
solutions (4 Mi/rn1, in Ependorif tubes) and preincubated for 30
minutes at 26°C. Samples (200 s.d) of the urine-inhibitor solutions
were added to predistributed solutions of NEP substrate and
SGAPI to yield a final concentration of 0.18 mM (The Km of the
substrate), as determined in preliminary experiments. Median
inhibitory concentration (IC50) was obtained from best-fit sigmoi-
dal dose-response curves, and inhibition constant (l() values were
calculated as 50% of the estimated IC50.
Analytical methods
Concentration of sodium in urine and plasma samples was
determined by flame photometry (Model 943, Instrumentational
Laboratories, Milan, Italy). Urinary creatinine was determined by
the alkaline picrate method (Jaffe reaction) using a commercially
available reagent kit (Ames Division, Miles Ltd., Milan, Italy).
Inulin concentration in plasma and urine was determined by the
anthrone method. GFR was equated with the clearance of inulin.
Data were analyzed statistically either by Student's t-test for
unpaired values or by analysis of variance for repeated measures,
as appropriate. The Dunnet test was applied for paired compar-
isons of means. A P value less than 0.05 was considered signifi-
cant.
Results
Assay conditions
The effects of variations in the pH and salt concentration of the
assay medium on urinary NEP activity are shown in Figure 1. At
37°C the activity was maximal at a pH of 7.91, with a sharp decline
at higher or lower pH values.
The increase in salt concentration of the assay medium also
markedly affected urinary NEP activity in a non-linear, hyperbolic
fashion. The increase was more rapid in the low physiological
range and slower at higher salt concentrations. Thus, in the
present study a pH of 7.91 and concentration of 100 mvi NaC1
were chosen as a standard assay for determination of NEP
activity.
Effect of inhibitors
The effects of incremental concentrations (10_h to i03 M) of
phosphoramidon and thiorphan on urinary NEP activity are
demonstrated in Figure 2. In this set of experiments the assay
conditions were changed (pH 7.5, temperature 26°C) in order to
duplicate the specific assay conditions used in the original publi-
cation [21]. A typical sigmoidal dose-response curve was obtained
that was of similar magnitude for both inhibitors (Fig. 2). The
calculated K1 values for phosphoramidon and for thiorphan were
1.23 0.8 and 0.87 0.1 nm, respectively.
Effects of high salt intake
Figure 3 depicts the average daily urinary sodium excretion rate
and urinary NEP activity during baseline (Days 1 to 5), high salt
intake (Days 6 to 10), and recovery (Days 11 to 16). Changing the
drinking water from tap water to 0.9% saline resulted in an abrupt
increase in daily sodium excretion, with a fourfold maximal
increase in absolute rate of daily sodium excretion (Fig. 3).
Concomitant with the increase in urinary sodium excretion, NEP
Fig. 1. Effects of variations in pH (A) and salt concentration (B) in assay
media on urina,y NEP activity. Data on pH effects are based on seven urine
samples assayed at 37°C and a 100 mM NaCI concentration. The line
representing the changes in enzyme activity due to variations in NaCI
concentration was generated by a sigmoidal curve fitting procedure based
on data from seven different urine samples assayed at pH 7.91.
activity in the urine increased in a time course and magnitude
similar to the change in sodium excretion. The maximal increase
in urinary NEP activity was observed on the second day of salt
loading, slightly preceding the peak natriuretic response (Fig. 3),
and remained elevated throughout the period of salt loading.
Urinary NEP activity increased both when expressed in absolute
terms (mOD/24 hr; data not shown) as well as when corrected for
urinary creatinine concentration to account for changes in urine
dilution and increased flow (Fig. 3). These changes in urinary
sodium and NEP activity returned to normal baseline values in the
recovery phase upon cessation of saline loading. In the control
group, maintained on tap water, urinary NEP activity remained
constant throughout the experiment.
Data on NEP activity in suspensions of isolated proximal
tubules from rats with normal (N = 4) and high salt intake, given
for five days, (N = 4) are shown in Figure 4. NEP activity was
significantly higher in proximal tubules derived from kidneys of
rats with high salt intake than in normal controls (441.5 43.4 vs.
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Fig. 2. Effects of NEP inhibitors, phosphoramidon (L), and thio,phan (•),
on urinaiy enzyme activity. NEP activity in 4 pA urine samples was assayed
in buffer containing 100 mat NaCI, 50 mat Tris-HCI, pH 7.5, at 26°C with
0.2 mat substrate. K and IC50 were calculated from plots by a computer-
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Fig. 4. NEP activity, expressed per pg protein, in isolated proximal nephron
preparations from rats maintained on tap water (control) and those on high
salt intake (0.9% saline) given for five days. Data are based on an average
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tubular segments were analyzed for enzyme activity under identical
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(N = 5) are shown by the open squares anday open circles, respectively.
244.4 24.7 mOD min1 mg' protein; P < 0.05). Thus, the istration of saline. Yet, in contrast to the chronic increase in
increase in urinary NEP activity following high salt intake was also sodium intake, acute saline expansion was not associated with any
reflected by similar alterations in enzyme activity in the proximal measurable increase in urinary NEP activity (Table 1).
nephron.
Discussion
Effects of acute saline expansion on urinary NEP The present study provides important and novel information
The effects of acute volume expansion by saline infusion on regarding the activity of NEP in the kidney and urine. Our
renal function and NEP activity in urine are summarized in Table findings indicate that NEP is present in significant amounts not
1. Infusion of 0.9% saline solution in an amount equivalent to 5% only in renal tissue, but also in the urine. Secondly, the activity of
of body weight resulted in a significant diuretic and natriuretic the enzyme in the urine displays characteristics similar to those
response, with no change in GFR or mean arterial BP. The reported in the kidney and other tissues in terms of susceptibility
increments in sodium excretion were of a magnitude (four- to to known inhibitors [21, 23] and pH regulation [24]. Finally, and
fivefold increase) similar to that observed during the oral admin- most important, the activity of NEP in urine and in isolated
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Table 1. Effect of volume expansion on the major determinants of renal function and on NEP activity in urine
Parameter Baseline
Volume expansion
20 mm 40 mm 60 mm 80 mm
V p1/mm 4.7 0.6 9.2 1.2 10.7 1.6 9.7 1.7 9.2 2.3a
UNaV p.Eqlmin 3.3 0.4 10.7 1.8 13.6 1.8 12.4 2.3a 12.9 2.3a
FENa % 1.1 0.2 3.1 0.5k 4.9 Q7 4.5 0.9 5.3 1.3a
GFR ml/min 2.1 0.4 2.5 0.3 2.2 0.5 2.0 0.3 1.9 0.3
BP mm Hg 109.8 4.5 115.0 2.2 108.0 8.1 108.8 7.9 115.0 2.9
NEP OD/minlmg inulin 0.1 0.02 0.11 0.02 0.12 0.03 0.14 0.03 0.14 0.04
Values are means SEM. V is urinary flow rate.
P < 0.05 compared with baseline
proximal tubules appears to be modulated by chronic salt loading,
but not by acute saline infusion. The latter finding suggests that
renal activity of NEP may be up-regulated as part of the adaptive
response to increased dietary salt intake.
Although the kidney is among the richest sources of NEP in the
body, the possibility that the enzyme may be secreted into the
urine has not gained much interest, nor has the contention that
urinary NEP may reflect the activity of the enzyme in the kidney.
The existing data in the literature regarding the activity of NEP in
the urine are scant and incomplete [17, 25]. As pointed out earlier,
the presence of NEP activity in human urine, with characteristics
similar to the renal enzyme, was previously reported by Skidgel et
al [17]. More recently it has been shown that urinary NEPactivity
may be altered in the early days following kidney transplantation
[26]. However, whether the latter finding has any pathophysiolog-
ical significance is unknown at present.
For reasons outlined earlier, we speculated that urinary NEP
must be primarily of renal origin. Therefore, it is logical to assume
that alterations in renal NEP activity should be reflected in the
final urine. Yet the possibility that other sources, in addition to
the kidney, may contribute to NEP activity in the urine must also
be considered. Thus, it is currently not known whether NEP is
present in or may be secreted from epithelial cells of the lower
urinary tract. A high content of NEP is found in the prostate and
epididymis [27], which may be another important source of
urinary NEP in the male rat. However, the observation that NEP
activity in the urine markedly increased following chronic salt
loading is highly suggestive of a renal rather than non-renal origin
of the enzyme. Taken together, arguments supporting the renal
origin of the urinary enzyme and the effect of salt loading on
urinary and renal NEP activity provide the rationale for using
urinary NEP activity as an index of the enzyme in the kidney.
Other physiological fluids such as cerebrospinal fluid and
amniotic fluid [23] and the synovial fluid [28) contain detectable
amounts of a soluble form of NEP. In the synovial fluid, NEP
activity seems to increase during inflammatory processes [28]. It is
noteworthy that in urine, as in other physiological fluids, the
nature of the soluble NEP is not clear. In particular, it is not
known whether the soluble peptidase is a secreted mature form
without the anchoring transmembrane domain or is released by a
shedding process as a consequence of cell turnover [18].
Our study has demonstrated for the first time that the activity of
the peptidase in the urine and renal tissue may be modulated by
chronic salt loading. Although the mechanism responsible for the
latter phenomenon has not been established, our finding suggests
that the renal activity of the peptidase may be regulated by sodium
balance or factor(s) related to it. Moreover, the finding that a
similar increment in urine flow and in sodium excretion produced
by acute i.v. saline loading was not associated with any detectable
change in urinary NEP activity suggests that the elevated enzyme
activity is not related to the increase in urinary flow rate or sodium
excretionperse. Rather, the finding that enzyme activity increased
both in proximal tubular segments and in the urine during salt
loading may imply that this phenomenon is an adaptive response
to the high dietary sodium intake. This, in turn, may be due to
regulatory action at the transcription level, the degree of protein
turnover, or a combination of both.
In several systems it has been shown that NEP is synthesized as
an 85-kDa non-glycosylated precursor with subsequent N-glyco-
sylation in the endoplasmic reticulum before the final processing
in the Golgi apparatus results in the active 93-kDa protein [29].
This biosynthetic process takes about 90 minutes, which may
explain why urinary NEP activity was augmented only during
chronic salt loading, but not in the short-term saline-infusion
studies.
It is well established that an increase in salt intake is associated
with activation of endogenous natriuretic systems as part of a
homeostatic response which prevents excessive accumulation of
salt in the body [30, 31]. The metabolic degradation of at least two
such systems, that is, that of ANP and bradykinin, is critically
dependent on NEP activity. It is possible that the increase in NEP
in the kidney is an adaptive response aimed at balancing the
enhanced activity of the natriuretic systems. Thus, the resetting of
both hormone action and its metabolic clearance to a higher level
of operation contributes to the efficient performance of such a
control system. This would allow the prompt increase of sodium
excretion during salt loading and, at the same time, may prevent
excessive salt wasting, by rapidly inactivating the hormone when
required.
The mechanism(s) modulating such an adaptive increase in
enzyme activity are, as yet, unknown. Further investigations will
be required to examine whether this phenomenon is secondary to
the activation of the natriuretic hormonal systems or if, alterna-
tively, the increases in both endogenous natriuretic agents and
renal NEP activity are triggered independently by the increase in
salt intake.
In summary, our findings suggest that the activity of NEP in the
kidney is modulated by salt loading. Moreover, this alteration may
be detected by measuring urinary NEP, which may serve as a
reliable index of the renal activity of the enzyme.
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